Aims: This analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using pooled data from 10 phase 3 ODYSSEY trials. blood pressure ≥130/85 mm Hg or diagnosis of hypertension; and fasting plasma glucose (FPG) ≥100 mg/dL. 1 MetS is a common syndrome with a rising prevalence worldwide, ranging from approximately 10% to 80% depending on regional variation and population
demographics. 1, 2 MetS is associated with an increased risk of cardiovascular (CV) disease (2-fold), type 2 diabetes mellitus (5-fold) and allcause mortality (1.5-fold). 1, 4, 5 However, multivariate analyses have shown that components typically associated with MetS (blood pressure, HDL-C and blood glucose), but not MetS itself, are predictors of prevalent coronary heart disease. 6 While statins are recommended as first-line therapy for reducing levels of LDL-C, not all patients achieve LDL-C lowering with statin therapy sufficient to optimally reduce their CV risk. Additionally, statin intolerance can limit dosage and potency of the statin used, which is a significant factor in the reduced efficacy of statin therapy for some patients. 7 In particular, patients with MetS may not achieve non-HDL-C goals following treatment with statins and other lipidlowering therapies (LLTs) 8 due to elevated TG levels, which are indicators of very-low-density lipoprotein and remnant cholesterol levels. 9 Individuals with MetS typically exhibit mixed dyslipidaemia, characterised by elevated TGs and lower HDL-C, both of which are often associated with elevated apolipoprotein (Apo) B and non-HDL-C levels. In such cases, non-HDL-C or ApoB may give a better estimate of the concentration of atherogenic particles than low-density lipoprotein cholesterol (LDL-C), and they have been suggested as alternative treatment targets to LDL-C for such individuals. 4 Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, has been approved in more than 40 countries, including the USA and the EU, for reducing elevated LDL-C levels. 10, 11 Individuals with metabolic syndrome have a range of clinical and metabolic characteristics that may impact the efficacy and/or safety of a PCSK9 inhibitor, including obesity, high triglycerides/low HDL-C, high blood glucose and insulin resistance. For example, PCSK9 appears to have a role in glucose metabolism and PCSK9 levels have been shown to correlate with glycaemic parameters and insulin resistance, although evidence is conflicting among different studies. 12, 13 Insulin signalling, which is known to influence LDL-receptor expression (the target of PCSK9), is often dysregulated in metabolic syndrome. 14 However, the use of PCSK9 inhibitors in individuals with metabolic syndrome is not well established. In the present study, we compared the efficacy and safety of alirocumab in patients with hypercholesterolaemia, with or without MetS, using data from 10 studies from the alirocumab ODYSSEY phase 3 clinical trial programme. This analysis contributes to a better understanding of the alirocumab target patient population.
| METHODS

| Study designs and pooling strategy
This analysis includes data from 10 phase 3 ODYSSEY studies (Figure 1 ), all of which have been described previously. 15 19 ), the MONO study (LDL-C 100-190 mg/ dL for all patients 21 ) and the HIGH FH study (LDL-C ≥160 mg/dL for all patients 23 ). All study protocols were approved by the appropriate review boards, and all patients provided written, informed consent.
For the current analysis, efficacy data were analysed in 4 pools according to alirocumab starting dose, control (placebo or ezetimibe) and use of background statin therapy (yes/no), as shown in Figure 1 .
In the first pool (LONG TERM, 19 measurements were not performed in the alirocumab phase 3 program; instead, we used BMI as a proxy, as has been done previously. 25 
| Endpoints
The current pooled analysis uses the same efficacy endpoints as the 
| Statistical analysis
Efficacy data were analysed using an intention-to-treat approach, as Table 1 and online in Table S1 . Patients had a mean age of 50 to 63 years across the groups; there was a greater proportion of males than females; and patients were mostly white (>85%). As per the selection criteria for this analysis, MetS patient groups had higher BMI, higher systolic blood pressure, a higher percentage of individuals with hypertension, higher FPG levels, lower levels of HDL-C, and higher levels of TGs compared to groups without MetS, for both placebo-and ezetimibe-controlled studies (Table 1) . A higher proportion of patients with MetS were receiving other LLTs in addition to statin (Table S1 ). (Tables S2 and S3) . 
| Efficacy
| Safety of alirocumab with respect to patients by MetS status
Time profiles of mean HbA1c and FPG levels over the treatment period showed that alirocumab had no clinically meaningful effect on these parameters compared to control treatments, for patients both with and without MetS (Figure 3 ). TEAE rates were generally similar across all treatment groups, irrespective of MetS status ( Table 2) affect the modest increases in HDL-C levels observed with alirocumab treatment.
Previous studies have shown that patients with MetS may not achieve their non-HDL-C goal following treatment with statins and other LLTs; in particular, the presence of MetS was shown to be a factor contributing to a greater difference between recommended vs attained non-HDL-C levels. 8 In the present analysis, a higher proportion of patients receiving alirocumab achieved both LDL-C and non-HDL-C goals compared with patients receiving placebo or ezetimibe, irrespective of MetS status.
With regards to safety, MetS status did not affect the incidence of TEAEs, with similar rates observed between the alirocumab and control groups. In this analysis, HbA1c and FPG levels were found to be unaffected by alirocumab in individuals both with and without MetS.
Some studies have suggested that statin therapy is associated with an increased incidence of type 2 diabetes. [29] [30] [31] In addition, a Mendelian randomization study found that PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR, the target of statin therapy) genetic variants associated with lower LDL-C were correlated with a reduced risk of CV events but also an increased risk of diabetes. 32 However, the authors emphasize that as PCSK9 antibodies bind extracellular PCSK9, their biological effects may not be the same as those observed with PCSK9 genetic variants which lower LDL-C levels over the course of a lifetime. 32 Furthermore, a pooled analysis of 10 ODYS-SEY phase 3 studies, with follow-up periods of between 24 and 104 weeks, indicated that there was no evidence of an effect of alirocumab on the transition to new-onset diabetes in those individuals without diabetes or with pre-diabetes at baseline. 33 Also of note, subgroup analyses of ODYSSEY trials have shown no effect of diabetes on the efficacy of alirocumab in terms of LDL-C reduction from baseline up to Week 104. 19, 34 Similarly, no effect of pre-diabetes on the efficacy and safety of alirocumab was observed. 35 Lastly, a prespecified analysis of the FOURIER clinical outcomes study with another PCSK9 inhibitor, evolocumab, showed no effect of diabetic status on efficacy and safety with follow-up to 2.2 years, and no effect of evolocumab on the incidence of new-onset diabetes. 36 Limitations of this analysis include the relatively short treatment periods of the ODYSSEY trials and the small number of patients in some subgroups. Waist circumference, a usual parameter for assessing obesity/MetS, was not measured in the trials. In addition, the analysis was performed on post-randomization groups, and some differences in baseline characteristics between the resulting alirocumab and control subgroups were noted. In order to provide sufficient numbers of patients for analysis, data were pooled from studies including patients with different clinical characteristics (eg, heterozygous familial hypercholesterolaemia, 15, 23 non-familial hypercholesterolaemia with prior cardiovascular disease or other risk factors, 17, 18 or statin intolerance 22 ), which may limit interpretation of results.
In summary, this pooled analysis showed that alirocumab produced significant reductions in both LDL-C and non-HDL-C, of similar magnitudes in individuals both with and without MetS, and was generally well tolerated, with no apparent effect on measures of glycaemic control.
